Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study
Open Access
- 27 October 2017
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (1) , e1-e4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.Current Drug Safety, 2016
- Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosisPediatric Blood & Cancer, 2013
- Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil countEuropean Journal of Haematology, 2013
- Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from ThailandAmerican Journal of Hematology, 2013
- The Safety, Tolerability, and Efficacy of a Liquid Formulation of Deferiprone in Young Children With Transfusional Iron OverloadJournal of Pediatric Hematology/Oncology, 2010
- A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic ResonanceCirculation, 2007
- Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood, 2006
- Deferiprone, efficacy and safetyIndian Journal of Pediatrics, 2004
- Safety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood, 2003
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992